Phase III, randomized, double-blind, placebo-controlled multicenter trial of daily everolimus plus weekly trastuzumab and vinorelbine in trastuzumab-resistant, advanced breast cancer (BOLERO-3).
Ruth O'Regan
Consultant or Advisory Role - Novartis
Research Funding - Genentech; Novartis
Mustafa Ozguroglu
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Fabrice Andre
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Masakazu Toi
Honoraria - Novartis
Research Funding - Novartis
Guy Heinrich Maria Jerusalem
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Research Funding - Novartis
Sharon Wilks
Honoraria - Novartis
Claudine Isaacs
Consultant or Advisory Role - AstraZeneca; Celgene; Enzon; Genentech
Binghe Xu
No relevant relationships to disclose
Norikazu Masuda
No relevant relationships to disclose
Francis P. Arena
Research Funding - Novartis
Denise Aysel Yardley
Consultant or Advisory Role - Novartis
Yoon Sim Yap
Honoraria - Novartis
Pabak Mukhopadhyay
Employment or Leadership Position - Novartis
Shyanne Douma
Employment or Leadership Position - Novartis
Mona El-Hashimy
Employment or Leadership Position - Novartis
Tanya Taran
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Tarek Sahmoud
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
David Edward Lebwohl
Employment or Leadership Position - Novartis
Luca Gianni
Consultant or Advisory Role - AstraZeneca; BioScience; Boehringer Ingelheim; Celgene; Genentech; GlaxoSmithKline; Novartis; Pfizer; Roche; Taiho Pharmaceutical